Personal preferences for avoiding gynecomastia (Stage 1)
Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Qualitative Stage
This project will ask men with prostate cancer and high-risk biochemical recurrence what trade-offs they'd make to avoid breast-related side effects like gynecomastia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | St Vincent's Hospital, Sydney Academic / other |
| Locations | 1 site (Sydney, New South Wales) |
| Trial ID | NCT07552922 on ClinicalTrials.gov |
What this trial studies
This qualitative study will use semi-structured interviews with men who have high-risk biochemical recurrence of prostate cancer, including men with and without prior androgen-deprivation therapy (ADT) exposure who have experienced breast-related side effects. Interviews will explore perceptions of gynecomastia and other breast-related harms, their impact on daily life and quality of life, and how patients weigh those harms against cancer control. Responses will be analyzed to define a set of attributes and levels that can be used in a later discrete choice experiment (DCE). Separate ethical approval will be sought for the subsequent DCE that uses the attributes developed here.
Who should consider this trial
Good fit: Men with high-risk biochemical recurrence of prostate cancer who are either yet to receive ADT/ARPI or who have received ADT/ARPI and experienced breast-related side effects are ideal candidates.
Not a fit: Men without high-risk biochemical recurrence, men with unrelated stages of prostate cancer, or those currently receiving psychiatric care related to their cancer would not be suitable and are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the work could lead to better information and decision aids that reflect what men value when choosing treatments that may cause breast-related side effects.
How similar studies have performed: While discrete choice experiments have been used to study trade-offs in cancer treatment broadly, using interviews specifically to develop gynecomastia-focused attributes is a relatively novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men with high-risk BCR PCa but no ADT+/-ARPI experience. * Men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment. Exclusion Criteria: • Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.
Where this trial is running
Sydney, New South Wales
- Kinghorn Cancer Centre — Sydney, New South Wales, Australia (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.